Prolonged activation of IL-5–producing ILC2 causes pulmonary arterial hypertrophy

Masashi Ikutani, Koichi Tsuneyama, Makoto Kawaguchi, Junya Fukuoka, Fujimi Kudo, Susumu Nakae, Makoto Arita, Yoshinori Nagai, Satoshi Takaki, Kiyoshi Takatsu

Research output: Contribution to journalArticlepeer-review

20 Citations (Scopus)


IL-33 is one of the critical cytokines that activates group 2 innate lymphoid cells (ILC2s) and mediates allergic reactions. Accumulating evidence suggests that IL-33 is also involved in the pathogenesis of several chronic inflammatory diseases. Previously, we generated an IL-5 reporter mouse and revealed that lung IL-5–producing ILC2s played essential roles in regulating eosinophil biology. In this study, we evaluated the consequences of IL-33 administration over a long period, and we observed significant expansion of ILC2s and eosinophils surrounding pulmonary arteries. Unexpectedly, pulmonary arteries showed severe occlusive hypertrophy that was ameliorated in IL-5– or eosinophil-deficient mice, but not in Rag2-deficient mice. This indicates that IL-5–producing ILC2s and eosinophils play pivotal roles in pulmonary arterial hypertrophy. Administration of a clinically used vasodilator was effective in reducing IL-33–induced hypertrophy and repressed the expansion of ILC2s and eosinophils. Taken together, these observations demonstrate a previously unrecognized mechanism in the development of pulmonary arterial hypertrophy and the causative roles of ILC2 in the process.

Original languageEnglish
Article numbere90721
JournalJCI Insight
Issue number7
Publication statusPublished - 2017 Apr 6

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Prolonged activation of IL-5–producing ILC2 causes pulmonary arterial hypertrophy'. Together they form a unique fingerprint.

Cite this